The best and most concise single source for state-of-the-art diagnosis and treatment of lung cancer –newly revised, updated, and expanded. Lung cancer has long been the number-one cause of death from cancer every year and the third most frequently diagnosed after breast and prostate cancers. In 2010, about 15% of all cancer diagnoses and 30% of all cancer deaths were due to lung cancer. Needless to say, there is a great need for more rapid advancements in diagnosis and treatment of this devastating disease.Here is the comprehensively revised, updated, and expanded edition of the well-established, evidence-based reference book that deals with the most recent advances in lung cancer prevention, screening, diagnosis, research, and treatment for the clinician. Edited and authored by leading authorities in the field, this Fourth Edition of the highly regarded Lung Cancer is better than ever –featuring nine new chapters along with seven re-formatted ones that are nearly brand new in content and approach. It covers Smoking Prevention and Cessation; Molecular Profiling; Somatic Genome Alterations in Human Lung Cancers; Management of Multi-Focal Bronchioloalveolar Carcinoma (BAC); Primary Tracheal Tumors; Predictive Tumor Biomarkers for EGFR Inhibitors; Non-Small Cell and Small-Cell Lung Carcinoma; and more.This Fourth Edition of Lung Cancer: Provides the very latest research in the identification of biomarkers to predict a high risk for developing lung cancer – vital for implementing screening, diagnosis, and prevention strategiesPresents the newest lung cancer staging system, as well as updated and cutting-edge surgical and radiation therapy techniques that make local tumor control more effective and less invasive while sparing normal tissuesDiscusses combined modality therapy and new chemotherapeutic agents which are yielding higher response rates and improved survival when used in the adjuvant setting or concurrent with highly sophisticated radiation or proton treatmentOffers novel and emergent approaches to preventative, diagnostic, and therapeutic modalities with an emphasis on the best evidence available from the latest studies and clinical trialsWith almost half of the revised and updated content being brand new, Lung Cancer, Fourth Edition, is an important and vital resource for all medical professionals and students involved in the care and treatment of those struck with this catastrophic illness.

Produktinformation

Utgivningsdatum2014-05-23
Mått193 x 244 x 33 mm
Vikt1 361 g
FormatInbunden
SpråkEngelska
Antal sidor616
Upplaga4
FörlagJohn Wiley and Sons Ltd
ISBN9781118468746

Tillhör följande kategorier

Onkologi inom Medicin

Jack A. Roth, MD, F.A.C.S., is Professor and Bud Johnson Clinical Distinguished Chair in the Department of Thoracic and Cardiovascular Surgery, Professor of Molecular and Cellular Oncology, Director of the W.M. Keck Center of Innovative Cancer Therapies, and Chief of the Section of Thoracic Molecular Oncology at the University of Texas MD Anderson Cancer Center in Houston, Texas, USA. James D. Cox, MD, is Professor and Head of the Department of Radiation Oncology at the University of Texas MD Anderson Cancer Center in Houston, Texas, USA.Waun Ki Hong, MD, D.M.Sc. (Hon.), is the American Cancer Society Professor and Samsung Distinguished University Chair in Cancer Medicine, as well as Professor and Head of the Division of Cancer Medicine and Professor in the Department of Thoracic/Head and Neck Medical Oncology at the University of Texas MD Anderson Cancer Center in Houston, Texas, USA.

Contributors, viiiPreface, xiii1 Smoking Prevention and Cessation, 1Alexander V. Prokhorov and Karen Suchanek Hudmon2 Lung Cancer Susceptibility and Risk Assessment Models, 25Xifeng Wu, Xia Pu, and Jie Lin3 Molecular Profiling, 48Lauren Averett Byers4 Somatic Genome Alterations in Human Lung Cancers, 67Marcin Imielinski, Peter S. Hammerman, Roman Thomas, and Matthew Meyerson5 Serum Proteomic Biomarkers, 90Mohamed Hassanein and David P. Carbone6 Molecular Biology of Lung Preneoplasia, 110Humam Kadara and Ignacio I. Wistuba7 Detection and Treatment of Preneoplastic Lesions, 129Rachel Jen and Stephen Lam8 Pathology of Adenocarcinoma, 144William D. Travis9 Management of Multifocal Bronchioloalveolar Carcinoma (BAC), 158Howard West10 Radiology and Lung Cancer Screening, 176Patricia de Groot and Reginald F. Munden11 Imaging Lung Cancer, 191Sonia L. Betancourt Cuellar, Edith M. Marom, and Jeremy J. Erasmus12 Staging of the Mediastinum, 202Mauricio Pipkin and Shaf Keshavjee13 Management of the Solitary Pulmonary Nodule, 214Min P. Kim14 Minimally Invasive Resections for Lung Cancer, 224Shanda H. Blackmon15 Extended Resections for Lung Cancer, 236Matthew A. Steliga and David C. Rice16 Bronchoscopic Interventions for Lung Cancer, 253Donald R. Lazarus and George A. Eapen17 Primary Tracheal Tumors, 267Francesco Sammartino and Paolo Macchiarini18 Adjuvant Chemotherapy Following Surgery for Lung Cancer, 278Kathryn A. Gold19 Neoadjuvant Chemotherapy for Resectable Non-Small Cell Lung Cancer, 290Christopher G. Azzoli and Katherine M.W. Pisters20 Image-Guided Radiation Therapy, 309Kenneth E. Rosenzweig and Sonal Sura21 Stereotactic Ablative Radiotherapy for Lung Cancer, 320Puneeth Iyengar and Robert D. Timmerman22 Proton Therapy, 338Joe Y. Chang and James D. Cox23 Combinations of Radiation Therapy and Chemotherapy for Non-small Cell and Small-Cell Lung Carcinoma, 353Daniel Gomez, Zhongxing Liao, Pierre Saintigny, and Ritsuko U. Komaki24 Individualized Radiotherapy by Dose Escalation and Altered Fractionation in Non-small Cell Lung Cancer, 379Heath D. Skinner, Ritsuko U. Komaki, Joe Y. Chang, and James D. Cox25 Molecular Target Treatment for Personalized Radiotherapy in Lung Cancer, 390Steven H. Lin and Ritsuko U. Komaki26 EGFR Tyrosine Kinase Inhibitors and Monoclonal Antibodies: Clinical Trial Review, 406Kathryn F. Mileham, Edward S. Kim, and William N. William Jr27 Mechanisms of Resistance to Epidermal Growth Factor Receptor (EGFR) in Non-small Cell Lung Cancer, 421Erminia Massarelli28 Predictive Tumor Biomarkers for EGFR Inhibitors, 435Lucia Kim, Geoffrey Liu, and Ming-Sound Tsao29 Immunologic Approaches to Lung Cancer Therapy, 454Jay M. Lee, Steven M. Dubinett, and Sherven Sharma30 Novel and Emerging Agents in NSCLC, 464Anne S. Tsao and Jack A. Roth31 Novel Clinical Trial Designs for Metastatic Lung Cancer, 479Vassiliki A. Papadimitrakopoulou32 Novel Statistical Models for NSCLC Clinical Trials, 488J. Jack Lee and Caleb T. Chu33 Tumor Microenvironment, Angiogenesis Biology, and Targeted Therapy, 505John V. Heymach and Tina Cascone34 Anti-angiogenic Agents in Metastatic NSCLC, 527Millie Das and Heather Wakelee35 Targeting ALK Rearrangements, 541Justin F. Gainor and Alice T. Shaw36 Non-small Cell Lung Cancers (NSCLC) with Mutations in BRAF, 557Renata Ferrarotto and George R. Simon37 Prognostic and Predictive Biomarker Signatures, 564Johannes R. Kratz and David M. Jablons38 Brain Metastasis from Lung Cancer, 572Ritsuko U. Komaki and Amol J. GhiaIndex, 591Color plate section between pages 146 and 147